CAPITOL HEALTH LIMITED (CAJ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAJ - CAPITOL HEALTH LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.92
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.36

01 Nov
2024

-0.015

OPEN

$0.38

-4.00%

HIGH

$0.38

4,195,531

LOW

$0.36

TARGET
$0.325 -9.6% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
CAJ: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.4 31.9 xxx
DPS (cps) xxx 0.9 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 10.1% 11.2% xxx
PE Ratio xxx N/A 1.1 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx N/A 3.1% xxx

Dividend yield today if purchased 3 years ago: 2.64%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.50

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 20/09 - ex-div 0.4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.4
DPS All xxxxxxxxxxxxxxx0.9
Sales/Revenue xxxxxxxxxxxxxxx234.8 M
Book Value Per Share xxxxxxxxxxxxxxx10.4
Net Operating Cash Flow xxxxxxxxxxxxxxx36.2 M
Net Profit Margin xxxxxxxxxxxxxxx-6.33 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-11.98 %
Return on Invested Capital xxxxxxxxxxxxxxx-5.89 %
Return on Assets xxxxxxxxxxxxxxx-4.66 %
Return on Equity xxxxxxxxxxxxxxx-11.98 %
Return on Total Capital xxxxxxxxxxxxxxx8.42 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx7.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx11 M
Long Term Debt xxxxxxxxxxxxxxx133 M
Total Debt xxxxxxxxxxxxxxx144 M
Goodwill - Gross xxxxxxxxxxxxxxx157 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx24 M
Price To Book Value xxxxxxxxxxxxxxx3.02

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx19.0 M
Capex % of Sales xxxxxxxxxxxxxxx8.11 %
Cost of Goods Sold xxxxxxxxxxxxxxx190 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx23 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

23/08/2024

1

Buy

$0.32

-11.11%

Commenting on FY24 results, Ord Minnett suggests 2H earnings margin expansion for Capitol Health augers well. FY24 adjusted profit beat forecasts by the broker and consensus by 2% and 10%, respectively.

The 2H margin of 21.6% compares to 18.4% in the previous corresponding period and 20.3% in the 1H of FY24, highlights the analyst.

The broker expects management is well positioned via procurement cost-outs in FY25 to drive margins back into the 22-23% range in the medium-term.

The Buy rating is retained, and the target slips to 32c from 33c. 

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.30 cents.
Ord Minnett forecasts a full year FY26 dividend of 1.20 cents and EPS of 1.70 cents.

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

28/08/2024

3

Neutral

$0.29

-19.44%

Capitol Health's FY24 earnings (EBITDA) outpaced consensus' forecasts by 2.4% and Jarden's forecasts by 0.3%, despite posting a top below consensus forecasts by -1.9%, thanks to strong cost control.

This yielded an EBITDA margin beat; margins increased to 21% vs Jarden's 20.4% as top-line growth outpaced rising labour costs, observes the broker.

EPS forecasts rise 1.4% in FY25; ease -0.4% in FY26; and rise 2.8% in FY27.

The broker believes the strong result, particularly the cost component, increases the attractiveness of the Integral Diagnostics ((IDX)) merger.

Neutral rating retained. Target price rises to 29c from 27c.

FORECAST
Jarden forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.40 cents.
Jarden forecasts a full year FY26 dividend of 1.10 cents and EPS of 1.70 cents.

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

CAJ STOCK CHART

FNArena News on CAJ

1
Australian Broker Call *Extra* Edition – Oct 24, 2024

Oct 24 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 26, 2024

Sep 26 2024 - Daily Market Reports
3
Rudi’s View: Defensives, Healthcare, Resources & Data Centres

Sep 19 2024 - Rudi's View
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-09-24

Sep 06 2024 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Sep 04, 2024

Sep 04 2024 - Daily Market Reports

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia